The document summarizes the evolution of medicine from surgery, drugs, and devices to stem and regenerative cell therapies. It discusses how stem cell therapies can treat various ischemic and chronic wound conditions. The document also reviews clinical trial results showing the safety and efficacy of mesenchymal stem cell therapies for cardiac conditions. It outlines what is known and unknown about optimizing stem cell treatments. Finally, it introduces the planned OKYANOS Heart Institute which will provide an EU-approved adipose-derived stem cell therapy for ischemic heart disease.

1. “The stream of that
river Okyanos, whence
is risen the seed of all
the immortals.”
Homer, Iliad 14.244ff
OKYANOS Heart Institute ©2012 All Rights Reserved

2. Evolution of Medicine
Surgery Drugs Devices Stem and
Regenerative Cells
OKYANOS Heart Institute ©2012 All Rights Reserved 2

3. “Every human walking the planet is a stem cell
product… (of) our father’s sperm and our mother’s
egg…When someone says they don’t believe in
stem cells they don’t understand their own
development. We’re walking stem cell products.”
OKYANOS Heart Institute ©2012 All Rights Reserved 3

4. Ischemic Conditions
Stroke
Cardiac
Crohn’s Fistulas
Radiation and Other
Chronic Wounds
PVD
Diabetic Wounds
OKYANOS Heart Institute ©2012 All Rights Reserved 4

5. AHA Cardiac Cell-Therapy Teach-in Nov, 2010
“Also, importantly, they
saw an effect of coronary
flow, so that’s an index
for new vessel
formation, so they knew
that these cells at least
induced some new
vessel formation, and
that resulted in improved
function of the heart.”
OKYANOS Heart Institute ©2012 All Rights Reserved 5

6. What Don’t We Know
Optimal # Best Delivery
of Cells Method
Optimal
Best Cell Type
# of Treatments
OKYANOS Heart Institute ©2012 All Rights Reserved 6

7. What We Do Know
Consistent, Strong,
Improving Signals
Cardiac Cell of Efficacy from
Therapy is Not (Yet) Clinical Trials which
a “Cure” Treated over 1000
Patients with
Mesenchymal Cells
OKYANOS Heart Institute ©2012 All Rights Reserved 7

8. Patients
Improved Reduced
Reduced
Mortality
Quality MACCE and
of Life Hospitalization
OKYANOS Heart Institute ©2012 All Rights Reserved 8

9. The Need for a Provision of Healthcare Service
Cell Society Feb., 2011
Cytori Expects EU-Approval
for No-Option CMI
OKYANOS Heart Institute ©2012 All Rights Reserved 9

10. PRECISE: Sustained Functional Benefit
20.0 Control
Cell
19.0 19
p < 0.05 p < 0.05
18.0
MVO2 (%)
17.2 17.1
17.0
16.6
16.0
15.0 15.5
15.3
Transplant
14.0
Baseline 6 Months 18 Months
OKYANOS Heart Institute ©2012 All Rights Reserved 10

11. PRECISE: Sustained Functional Benefit
Safe and Lower
Infarct Feasible Cardiac
MVO2 METS
Size Through Mortality
18 Months Rate
Significant Change Significant Change 8.2% Change At Avg. Follow Up
at 18 Months at 18 Months at 6 Months of 28 Months:
Correlates to Significant Change 2/6 Placebo Pts
Improved Survival Died of Cardiac
Causes
≤ 14 = 47% 1/21 Treated Pts
1 Yr Survival Rate Died of Cardiac
Causes
OKYANOS Heart Institute ©2012 All Rights Reserved 11

12. What Patients Expect
Chief
Medical
Officer
Cell
Next-Gen Processing
Catheter Device
U.S.
State of
the Art
Center of Surgical
Center
Cath Lab
Excellence Standards
EU-
Approved Patient
Therapy Registry
(Expected) Hospitality
Trained-
Staff
Celution One is not approved in U.S.
OKYANOS Heart Institute ©2012 All Rights Reserved 12

13. OKYANOS Heart Institute
First in world to provide an (expected) EU-Approved cardiac
cell therapy to patients with no-option ischemic heart disease
Autologous Adipose-Derived Stem and Regenerative Cells
via intramyocardial injection
Center of Excellence built to OKYANOS specifications and U.S.
surgical center standards in Freeport, Bahamas
Expected opening Summer, 2012
OKYANOS Heart Institute ©2012 All Rights Reserved 13

14. OKYANOS Heart Institute
OKYANOS Heart Institute ©2012 All Rights Reserved 14